Just Published: "Global Hemophilia B Market 2015-2019 - Industry Analysis"

Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.

Technavio's analysts forecast the global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.

Technavio's report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.

Full Report Details at
- http://www.fastmr.com/prod/1055994_global_hemophilia_20152019.aspx?afid=301

Key regions

* Americas
* APAC
* EMEA

Key vendors

* Baxter
* Grifols
* Novo Nordisk
* Pfizer

Other prominent vendors

* Alnylam
* Amarna
* Asklepios
* Biogen
* Catalyst Biosciences
* CSL Behring
* Dimension Therapeutics
* Dong-A Scio
* Emergent BioSolutions

Key market driver

* Prophylactic treatment
* For a full, detailed list, view our report

Key market challenge

* High cost of therapy
* For a full, detailed list, view our report

Key market trend

* New technological advancements
* For a full, detailed list, view our report

Key questions answered in this report

* What will the market size be in 2019 and what will the growth rate be?
* What are the key market trends?
* What is driving this market?
* What are the challenges to market growth?
* Who are the key vendors in this market space?
* What are the market opportunities and threats faced by the key vendors?
* What are the strengths and weaknesses of the key vendors?

Companies Mentioned in this Report: Baxter, Grifols, Novo Nordisk and Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen, Catalyst Biosciences, CSL Behring, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Kedrion, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics, Swedish Orphan Biovitrum, uniQure.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- Global Hemophilia A Market 2015-2019 - Industry Analysis
- Global Membrane Market in Pharmaceutical Industry 2015-2019
- PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023
- Hemophilia B - Pipeline Review, H1 2015
- Surface Analysis Market - Global Forecast to 2020